Articles tagged "Prophylaxis"

2018 American Transplant Congress
Outpatient Prophylactic Valganciclovir Dose Optimization Post-Renal Transplant
M. Spinner,¹ V. Athans,¹ C. Koval.²
¹Dept. of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Dept. of Infectious Diseases, Cleveland Clinic, Cleveland, OH.
Purpose: Renal function rapidly changes post-transplant requiring dose adjustment of CMV prophylaxis. We describe valganciclovir (VGCV) dosing accuracy in the outpatient setting and its associated…
2018 American Transplant Congress
The Incidence and Outcome of Isolated Distal Deep Vein Thrombosis in Kidney Transplant Recipient
M. Kim, J. Hwang, S. Kim, S. Park, I. Moon, J. Kim.
Surgery, The Catholic University of Korea, Seoul, Republic of Korea.
Introduction Isolated distal deep vein thrombosis (IDDVT) in kidney transplantation recipient (KTR) is difficult to make decision because it is not common in Korean and…
2018 American Transplant Congress
Single vs. Multi-Drug Antibiotic Prophylaxis for Continuous-Flow Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis
S. Patel,¹ J. Choi,¹ E. Moncho Escrivà,² S. Rizvi,¹ L. Samuels,¹ J. Luc,³ R. Morris,¹ H. Massey,¹ V. Tchantchaleishvili,¹ N. Aburjania.⁴
¹Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, PA; ²University of Granada, Granada, Spain; ³University of Alberta, Edmonton, AB, Canada; ⁴Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA.
Purpose: Despite the fact that infection remains a major complication of continuous-flow left ventricular assist device (CF-LVAD) therapy, an optimal antimicrobial surgical infection prophylaxis (SIP)…
2017 American Transplant Congress
Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.
J. Lockridge,¹ E. Langewisch,² D. Basuli,¹ A. Olyaei,³ C. Shaut,⁴ D. Norman.¹
¹Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; ²Nephrology, University of Nebraska, Omaha, NE; ³Pharmacy, Oregon Health and Sciences University, Portland, OR; ⁴Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR
Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…
2017 American Transplant Congress
Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience.
A. Baghban,¹ K. Belfield,² M. Azar,¹ E. Cohen,² M. Malinis.¹
¹Infectious Diseases, Yale University, New Haven, CT; ²Pharmacy, YNHH, New Haven, CT
IntroductionCurrent guidelines on cytomegalovirus (CMV) prophylaxis following organ transplant recommend using valganciclovir (VGCV) 900 mg daily for high (CMV D+/R-) and intermediate (CMV R+) risk…
2017 American Transplant Congress
High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients.
J. Fose,¹ E. McCreary,¹ M. Jorgenson,¹ M. Lucey,² J. Smith.²
¹Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI; ²Medicine, University of Wisconsin Hospital and Clinics, Madison, WI
Purpose: Evaluate the incidence of cytomegalovirus (CMV) infection in seropositive (R+) solid organ transplant recipients (SOT) receiving high-dose acyclovir (HD-A, 800 mg QID) prophylaxis.Methods: Retrospective…
2017 American Transplant Congress
Vancomycin Prophylaxis for Prevention of Clostridium difficile Recurrence in Renal Transplant Patients.
L. Spliner,¹ J. Fose,¹ G. Leverson,² J. Smith,³ C. Saddler,³ M. Jorgenson.¹
¹Pharmacy, UW Health, Madison, WI; ²Surgery, UW Health, Madison, WI; ³Medicine, UW Health, Madison, WI
Purpose: Clostridium difficile infection (CDI) is higher in solid organ transplant recipients. IDSA/SHEA guidelines do not recommend prophylactic (PROPH) vancomycin (VANC) or metronidazole in CDI…
2017 American Transplant Congress
Efficacy of Trimethoprim-Sulfamethoxazole Prophylaxis for Nocardia in Solid Organ Transplant Recipients (SOTRs): Systematic Review and Meta-Analysis.
A. Alsharidi,¹ A. Gonzalez,² C. Rotstein,³ A. Humar,³ D. Kumar,³ S. Husain.³
¹Medicine, Infectious Diseases, McMaster University, Hamilton, ON, Canada; ²Medicine, Infectious Diseases, University of Florida, Gainesville, FL; ³Multi-Organ Transplant, Transplant Infectious Diseases, University of Toronto, Toronto, ON, Canada
Background:There are increasing reports of breakthrough Nocardia infection in patients taking Trimethoprim-Sulfamethoxazole (TMP-SMX) prophylaxis post SOT. We performed a meta-analysis to evaluate the effectiveness of…
2017 American Transplant Congress
Spousal Transmission of Hepatitis B from a Hepatitis B Core Antibody Positive Liver Transplant Recipient – A Case Report.
J. Gripshover, K. Hidalgo, B. Ravichandran.
University of Maryland Medical Center, Baltimore, MD
IntroductionGiven the shortage of donor organs, hepatitis B core antibody positive (HBcAb+) donors have been utilized to increase access to transplantation. It is well established…
2017 American Transplant Congress
Antibiotic Prophylaxis Against Urinary Tract Infections After Renal Transplant.
P. Klem,¹ J. Gralla,² D. Chang,¹ A. Wiseman,² S. Davis,² J. Cooper.²
¹Pharmacy, University of Colorado, Aurora, CO; ²Nephrology, University of Colorado, Aurora, CO
Urinary tract infections (UTI) are the most common infectious complication after kidney transplant. Previous research at our center showed sulfamethoxazole/trimethoprim (SMX/TMP) use for PCP prophylaxis…